RxDoctor Payments Data

Matthew Miller, DO

Hematology & Oncology · Joplin, MONPI 1558474122

Payments from drug & device makers

$7,615in general payments, 2019–2025

Across 292 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$536
  • Johnson & Johnson$528
  • Lilly USA, LLC$434
  • Amgen$419
  • Daiichi Sankyo Inc.$378
  • Pfizer$356
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$6,49985%
  • Education$1,11615%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis25$536
Johnson & Johnson(2 entities)16$528
Lilly USA, LLC9$434
Amgen13$419
Daiichi Sankyo Inc.9$378
Pfizer26$356
Gilead(2 entities)17$355
Sanofi10$350
AstraZeneca14$349
Regeneron Healthcare Solutions, Inc.8$325
E.r. Squibb & Sons, L.L.C.15$288
Bristol Myers Squibb10$180
Merck8$175
AbbVie6$174
Incyte Corporation8$164
Genentech USA, Inc.8$162
BTG International Inc.2$159
Galvanize Therapeutics, Inc1$156
Inari Medical, Inc.1$139
Karyopharm Therapeutics Inc.6$131
Takeda Pharmaceuticals U.S.A., Inc.3$111
Janssen Scientific Affairs, LLC3$107
Eisai Inc.6$107
Taiho Oncology, Inc.5$101
GSK5$86
Array Biopharma Inc3$85
Stemline Therapeutics Inc.3$78
Exelixis Inc.3$69
Ipsen Biopharmaceuticals, Inc3$66
Caris MPI, Inc.1$59
Boehringer Ingelheim2$58
Jazz Pharmaceuticals Inc.2$54
Pharmaessentia USA Corporation2$52
Pharmacosmos Therapeutics Inc.2$49
Sobi, Inc2$48
Sumitomo Pharma America, Inc.2$47
Genmab U.S., Inc.2$46
AVEO Pharmaceuticals, Inc.2$45
Bayer2$45
Pharmacyclics LLC, An Abbvie Company2$41
Puma Biotechnology, Inc.2$41
Foundation Medicine, Inc.2$40
Blueprint Medicines Corporation2$37
Rigel Pharmaceuticals, Inc.2$35
Seagen Inc.2$33
Beone Medicines USA, Inc.1$32
Astellas Pharma US Inc1$32
Springworks Therapeutics, Inc.1$29
Recordati_rare_diseases_inc.1$26
Morphosys, US Inc.1$25
Myovant Sciences Inc.1$22
Coherus Oncology, Inc.1$22
Tempus AI, Inc1$22
EMD Serono, Inc.1$21
Novocure Inc.1$18
Agios Pharmaceuticals, Inc.1$16
Acrotech Biopharma Inc.1$14
Clovis Oncology, Inc.1$14
Dova Pharmaceuticals1$13
G1 Therapeutics, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,615 in reported general payments places this provider in the 55th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$114,069
Medicare patients
518
Services billed
1,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide24$534,444
BrukinsaZanubrutinib31$458,624
VonjoPacritinib Citrate12$323,011
IbrancePalbociclib17$248,960
RevlimidLenalidomide14$241,822
JaypircaPirtobrutinib12$236,420
ImbruvicaIbrutinib13$233,667
XtandiEnzalutamide14$188,601
DopteletAvatrombopag Maleate11$121,094
Abiraterone Acetate16$38,708
OxycontinOxycodone Hcl15$25,302
XareltoRivaroxaban17$17,168
EliquisApixaban27$15,365
Xtampza ErOxycodone Myristate11$12,162
Letrozole321$7,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$288$534,44424 claims
PfizerIbrance, Eliquis$356$264,32544 claims
Bristol Myers SquibbRevlimid$180$241,82214 claims
Lilly USA, LLCJaypirca$434$236,42012 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$41$233,66713 claims
Astellas Pharma US IncXtandi$32$188,60114 claims
Dova PharmaceuticalsDoptelet$13$121,09411 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$107$38,70816 claims
Johnson & JohnsonXarelto$528$17,16817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 211 hematology & oncology providers in Missouri.

Other hematology & oncology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →